<DOC>
	<DOCNO>NCT02045732</DOCNO>
	<brief_summary>PF-06342674 ( RN168 ) , develop treatment multiple sclerosis ( MS ) , antibody bind inhibits human interleukin-7 receptor , component potentially involved MS. PF-06342674 ( RN168 ) expect play role slow progression disease .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of PF-06342674 ( RN168 ) In Subjects With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Women men age 1855 yr . Confirmed diagnosis Multiple Sclerosis ( MS ) accord 2010 revision McDonald Criteria . Expanded Disability Status Scale ( EDSS ) 05 , inclusive . Relapse episode MS within 2 week enrollment . Primary progressive MS without relapse component . Intolerant unwilling undergo MRI scanning . Treatment disease modify agent 6 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MRI</keyword>
</DOC>